CENTER FOR VETERINARY BIOLOGICS NOTICE NO. 13-10

TO: Biologics Licensees, Permittees, and Applicants
    Directors, Center for Veterinary Biologics
    Veterinary Services Leadership Team

      Director
      Center for Veterinary Biologics

SUBJECT: Changes to the Rabies Virus NIH Potency Test Validity Requirements

I. PURPOSE

This Notice informs licensees, permittees, and applicants of the Center for Veterinary Biologics (CVB) intent to eliminate the median lethal dose (LD50) upper limit for the challenge virus as a validity requirement when conducting the Rabies Virus NIH potency test.

II. BACKGROUND

Supplemental Assay Method (SAM) 308 describes the current procedure for conducting the Rabies Virus NIH potency test according to the requirements specified in Title 9, Code of Federal Regulations, Part 113.209(d)(3). For a valid challenge, SAM 308 requires the LD50 to be between 12 and 50 LD50 before determining a serial’s relative potency (RP) value. This has required repeating otherwise satisfactory tests if the challenge LD50 was greater than the upper limit. Repeated testing has demonstrated the serials have acceptable potency in a valid NIH assay. CVB has found no indication an upper limit is necessary for test validity. In an effort to reduce the number of animals required for rabies testing, the CVB intends to eliminate the upper limit LD50 for a valid challenge when conducting the Rabies Virus NIH potency test.

III. POLICY

The CVB has eliminated the upper limit LD50 for a valid challenge as a validity requirement when conducting the Rabies Virus NIH potency test. For a valid challenge, the LD50 is now ≥ 12. SAM 308 will be amended to reflect this change.

IV. IMPLEMENTATION/ APPLICABILITY

This change will be effective immediately.